Search

Borregaard ASA

Fermé

185.4 0.65

Résumé

Variation du prix de l'action

24h

Actuel

Min

182.2

Max

185.4

Chiffres clés

By Trading Economics

Revenu

122M

251M

Ventes

292M

2B

P/E

Moyenne du Secteur

21.189

58.43

BPA

2.52

Rendement du dividende

2.29

Marge bénéficiaire

12.328

Employés

1,174

EBITDA

505M

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.29%

5.61%

Prochains Résultats

16 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-663M

19B

Ouverture précédente

184.75

Clôture précédente

185.4

Borregaard ASA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 mai 2025, 23:25 UTC

Actions en Tendance

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 mai 2025, 21:57 UTC

Acquisitions, Fusions, Rachats

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 mai 2025, 21:29 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefónica's Operations in Uruguay

21 mai 2025, 21:01 UTC

Principaux Mouvements du Marché

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 mai 2025, 20:51 UTC

Acquisitions, Fusions, Rachats

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion

21 mai 2025, 23:49 UTC

Market Talk

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 mai 2025, 23:37 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 mai 2025, 23:33 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mai 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mai 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mai 2025, 23:32 UTC

Market Talk
Acquisitions, Fusions, Rachats

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 mai 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 mai 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 mai 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 mai 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 mai 2025, 23:28 UTC

Résultats

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 mai 2025, 23:27 UTC

Résultats

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 mai 2025, 23:26 UTC

Résultats

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 mai 2025, 23:26 UTC

Résultats

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 mai 2025, 23:26 UTC

Résultats

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 mai 2025, 23:23 UTC

Acquisitions, Fusions, Rachats

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mai 2025, 23:22 UTC

Acquisitions, Fusions, Rachats

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mai 2025, 23:20 UTC

Acquisitions, Fusions, Rachats

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mai 2025, 23:18 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 mai 2025, 21:42 UTC

Actualités
Acquisitions, Fusions, Rachats

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 mai 2025, 21:14 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefónica's Ops in Uruguay

21 mai 2025, 21:07 UTC

Actualités

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 mai 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

21 mai 2025, 20:59 UTC

Actualités

Walmart to Cut 1,500 Jobs -- WSJ

21 mai 2025, 20:52 UTC

Résultats

Snowflake Stock Pops After Earnings Beat -- Barrons.com

Borregaard ASA prévision

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Borregaard ASA

Borregaard ASA engages in the development, production, and marketing of specialized biomaterials and biochemicals in Norway, rest of Europe, the United States, Asia, and internationally. It operates in three segments: BioSolutions, BioMaterials, and Fine Chemicals. The BioSolutions segment develops, produces, and sells biopolymers for various applications, such as agrochemicals, batteries, industrial binders, and construction; and biovanillin for flavor and fragrance companies, as well as for food and beverage industry. The BioMaterials segment offers specialty cellulose for use as a raw material in the production of cellulose ethers, cellulose acetate, and other specialty products; and cellulose fibrils for industrial applications. The Fine Chemicals segment provides fine chemical intermediates for contrast agents; and advanced bioethanol products. Borregaard ASA was incorporated in 2012 and is headquartered in Sarpsborg, Norway.